Browse > Article

Cell Death Induction Mechanism of Non-small Cell Lung Cancer Cell Line, NCI-H1703 by Docetaxel  

Ha Hyeon-Cheol (Department of Thoracic and Cardiovascular Surgery, Collage of Medicine, Pusan National University)
Song Seung-Hwan (Department of Thoracic and Cardiovascular Surgery, Collage of Medicine, Pusan National University)
Park Chin-Su (Department of Thoracic and Cardiovascular Surgery, Collage of Medicine, Pusan National University)
Kim Jong-Won (Department of Thoracic and Cardiovascular Surgery, Collage of Medicine, Pusan National University)
Kim Yeong-Dae (Department of Thoracic and Cardiovascular Surgery, Collage of Medicine, Pusan National University)
Publication Information
Journal of Chest Surgery / v.39, no.9, 2006 , pp. 668-673 More about this Journal
Abstract
Background: Docetaxel has been effectively used as an anti-cancer chemotherapuetic agent for various tumor treatments including lung cancer. However, the cell death induction mechanism(s) involved with docetaxel treatment in lung cancer cells has not been known yet. Material and Method: In the present study, the cellular and biochemical changes of NCI-H1703 cells (non-small cell lung cancer cell line, p53-mutant) after docetaxel treatment have been monitored by flow cytometry, fluorescence microscopy and western blot. Result: Docetaxel treatment significantly resulted in decrease of S phase as well as increase of G2 phase, and consequently evoked an increase of cell death in NCI-H1703 cells. After docetaxel exposure the activations of caspase-3 and caspase-9 were detected. Conclusion: Take together, it is suggested that the docetaxel induces NCI-H1703 cell death by caspase-9 and caspase-3 dependent mitochondrial apoptotic pathway.
Keywords
Carcinoma, non-small cell, lung; Neoplasm biology; Cell death;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Calderoni A, Cerny T. Taxanes in lung cancer. A review with focus on the European experience. Crit Rev Oncol Hematol 2001;38:105-27   DOI   ScienceOn
2 Yoon SJ, Lee H, Shin Y, Kim YI, Kim CY, Chang H. Estimation of the burden of major cancers in Korea. J Korean Med Sci 2002;17:604-10   DOI
3 Zelivianski S, Spellman M, Kellerman M, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003;107:478-85   DOI   ScienceOn
4 Illidge TM, Cragg MS, Fringes B, Olive P, Erenpreisa JA. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol Int 2000;24: 621-33   DOI   ScienceOn
5 Huisman C, Ferreira CG, Broker LE, et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCL-H460. Clin Cancer Res 2002;8:596
6 Ferreira CG, Tolis C, Span SW, et al. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 2000;6: 203-12
7 Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003;29:407-15   DOI   ScienceOn
8 Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Canc Agents 2003;3:291-306   DOI   ScienceOn
9 Cullen M. Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax 2003;58: 352-6   DOI   ScienceOn
10 Langer CJ. Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Invest New Drugs 2000;18: 17-28   DOI   ScienceOn
11 Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by antimicrotubule agents in human lung cancers. Am J Pathol 2003;163:1109-16   DOI   ScienceOn
12 Georgoulias V. Docetaxel (taxotere) in the treatment of nonsmall cell lung cancer. Curr Med Chem 2002;9:869-77   DOI   ScienceOn
13 Weigel TL, Lotze MT, Kim PK, Amoscato AA, Luketich JD, Odoux C. Paclitaxel-induced apoptosis in non-small cell lung cancer cell lines is associated with increased caspase-3 activity. J Thorac Cardiovasc Surg 2000;119:795-803   DOI   ScienceOn
14 Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362: 362-9   DOI   ScienceOn
15 Morris SM. A role for p53 in the frequency and mechanism of mutation. Mutat Res 2002;511:45-62   DOI   ScienceOn
16 King TC, Akerley W, Fan AC, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000;89:769-73   DOI   ScienceOn
17 Kolfschoten GM, Hulscher TM, Duyndam MC, Pinedo HM, Boven E. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel. Biochem Pharmacol 2002;63:733-43   DOI   ScienceOn
18 Wang H. Combined effect of docetaxel and cisplatin for nonsmall cell lung cancer cell lines in vitro. Nagoya J Med Sci 2000;63:129-37